ACS Medicinal Chemistry Letters
LETTER
of pathway selective inhibitors of NF-kB activation. Further work
focused on improvement of potency and pharmacological profile
of the probe molecule 1c is underway.
M. A.; Foster, S. J.; Mak, T. W.; Nu~nez, G.; Inohara, N. An essential role
for Nod1 in host recognition of bacterial peptidoglycan containing
diaminopimelic acid. Nat. Immunol. 2003, 4, 702–707.
(18) Uehara, A.; Fujimoto, Y.; Kawasaki, A.; Kusumoto, S.; Fukase,
K.; Takada, H. Meso-Diaminopimelic Acid and Meso-Lanthionine,
Amino Acids Specific to Bacterial Peptidoglycans, Activate Human
Epithelial Cells through NOD1. J. Immunol. 2006, 177, 1796–1804.
(19) Girardin, S. E.; Travassos, L. H.; Herve, M.; Blanot, D.; Boneca,
I. G.; Philpott, D. J.; Sansonetti, P. J.; Mengin-Lecreulx, D. Peptidogly-
can molecular requirements allowing detection by Nod1 and Nod2.
J. Biol. Chem. 2003, 278, 41702–41708.
’ ASSOCIATED CONTENT
S
Supporting Information. Synthetic procedures, charac-
b
terization of final products, biological assay protocols and data,
and pharmacology profile. This material is available free of charge
(20) Franchi, L.; Amer, A.; Body-Malapel, M.; Kanneganti, T. D.;
Ozoren, N.; Jagirdar, R.; Inohara, N.; Vandenabeele, P.; Bertin, J.; Coyle,
A.; Grant, E. P.; Nu~nez, G. Cytosolic flagellin requires Ipaf for activation
of caspase-1 and interleukin 1beta in salmonella-infected macrophages.
Nat. Immunol. 2006, 7, 576–582.
’ AUTHOR INFORMATION
Corresponding Author
*Tel: 407-745-2062. E-mail: groth@sanfordburnham.org.
(21) Miao, E. A.; Alpuche-Aranda, C. M.; Dors, M.; Clark, A. E.;
Bader, M. W. Cytoplasmic flagellin activates caspase-1 and secretion of
interleukin-1 beta via Ipaf. Nat. Immunol. 2006, 7, 569–575.
(22) Kanazawa, N.; Okafuji, I.; Kambe, N.; Nishikomori, R.; Nakata-
Hizume, M.; Nagai, S.; Fuji, A.; Yuasa, T.; Manki, A.; Sakurai, Y.;
Nakajima, M.; Kobayashi, H.; Fujiwara, I.; Tsutsumi, H.; Utani, A.;
Nishigori, C.; Heike, T.; Nakahata, T.; Miyachi, Y. Early-onset sarcoi-
dosis and CARD15 mutations with constitutive nuclear factor-kB
activation: common genetic etiology with Blau syndrome. Blood 2005,
105, 1195–1197.
Funding Sources
The financial support for this research was provided by the
Molecular Libraries Initiative of the National Institutes of Health
Roadmap for Medical Research NIH Grants 5U54 HG005033
and 1 R03 MH084844 to J.C.R.
’ REFERENCES
(1) Akira, S.; Uemastu, S.; Takeuchi, O. Pathogen recognition and
innate immunity. Cell 2006, 124, 783–801.
(2) Dangl, J. L.; Jones, J. D. Plant pathogens and integrated defence
responses to infection. Nature 2001, 411, 826–833.
(23) Carneiro, L. A.; Travassos, L. H.; Girardin, S. E. Nod-like
receptors in innate immunity and inflammatory diseases. Ann. Med.
2007, 39, 581–593.
(24) Inohara, N.; Ogura, Y.; Fontalba, A.; Gutierrez, O.; Pons, F.;
Crespo, J.; Fukase, K.; Inamura, S.; Kusumoto, S.; Hashimoto, M.;
Foster, S. J.; Moran, A. P.; Fernandez-Luna, J. L.; Nu~nez, G. Host
recognition of bacterial muramyl dipeptide mediated through
NOD2: Implications for Crohn's disease. J. Biol. Chem. 2003, 278,
5509–5512.
(25) Hugot, J. P.; Chamaillard, M.; Zouali, H.; Lesage, S.; Cezard,
J. P.; Belaiche, J.; Almer, S.; Tysk, C.; O'Morain, C. A.; Gassull, M.;
Binder, V.; Finkel, Y.; Cortot, A.; Modigliani, R.; Laurent-Puig, P.;
Gower-Rousseau, C.; Macry, J.; Colombel, J. F.; Sahbatou, M.; Thomas,
G. Association of NOD2 leucine-rich repeat variants with susceptibility
to Crohn's disease. Nature 2001, 411, 599–603.
(26) Ogura, Y.; Bonen, D. K.; Inohara, N.; Nicolae, D. L.; Chen,
F. F.; Ramos, R.; Britton, H.; Moran, T.; Karaliuskas, R.; Duerr, R, H.;
Achkar, J.-P.; Brant, S. R.; Bayless, T. M.; Kirschner, B. S.; Hanauer, S. B.;
Nu~nez, G.; Cho, J. H. A frameshift mutation in NOD2 associated with
susceptibility to Crohn's disease. Nature 2001, 411, 603–606.
(27) Miceli-Richard, C.; Lesage, S.; Rybojad, M.; Prieur, A. M.;
Manouvrier-Hanu, S.; Hafner, R.; Chamaillard, M.; Zouali, H.; Thomas,
G.; Hugot, J. P. CARD15 mutations in Blau syndrome. Nat. Genet. 2001,
29, 19–20.
(28) Maeda, S.; Hsu, L. C.; Liu, H.; Bankston, L. A.; Iimura, M.;
Kagnoff, M. F.; Eckmann, L.; Karin, M. Nod2 mutation in Crohn's
disease potentiates NF-kappa B activity and IL-1beta processing. Science
2005, 307, 734–738.
(3) Medzhitov, R. Toll-like receptors and innate immunity. Nature
Rev. Immunol. 2001, 1, 135–145.
(4) Jones, D. A.; Takemoto, D. Plant innate immunity-direct and
indirect recognition of general and specific pathogen-associated mol-
ecules. Curr. Opin. Immunol. 2004, 16, 48–62.
(5) Kumagai, Y.; Takeuchi, O.; Akira, S. Pathogen recognition by
innate receptors. J. Infect. Chemother. 2008, 14, 86–92.
(6) Akira, S. Pathogen recognition by innate immunity and its
signaling. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009, 85, 143–156.
(7) Meylan, E.; Tschopp, J.; Karin, M. Intracellular pattern recogni-
tion receptors in the host response. Nature 2006, 442, 39–44.
(8) Chamaillard, M.; Girardin, S. E.; Viala, J.; Philpott, D. J. Nods,
Nalps and Naip: Intracellular regulators of bacterial-induced inflamma-
tion. Cell. Microbiol. 2003, 5, 581–592.
(9) Inohara, N.; Nu~nez, G. NODs: Intracellular proteins involved in
inflammation and apoptosis. Nature Rev. Immunol. 2003, 3, 371–382.
(10) Strober, W.; Murray, P. J.; Kitani, A.; Watanabe, T. Signalling
pathways and molecular interactions of NOD1 and NOD2. Nature Rev.
Immunol. 2006, 6, 9–20.
(11) Inohara, N.; Nu~nez, G. The NOD: A signaling module that
regulates apoptosis and host defense against pathogens. Oncogene 2001,
20, 6473–6481.
(12) Inohara, N.; Ogura, Y.; Nun~ez, G. Nods: A family of cytosolic
proteins that regulate the host response to pathogens. Curr. Opin.
Immunol. 2002, 5, 76–80.
(13) Kawai, T.; Akira, S. The roles of TLRs, RLRs and NLRs in
pathogen recognition. Int. Immunol. 2009, 21, 317–337.
(14) Rietdijk, S. T.; Burwell, T.; Bertin, J.; Coyle, A. J. Sensing
intracellular pathogens-NOD-like receptors. Curr. Opin. Pharmacol.
2008, 8, 261–266.
(15) Murray, P. J. NOD proteins: An intracellular pathogen-recog-
nition system or signal transduction modifiers? Curr Opin. Immunol.
2005, 17, 352–358.
(16) Girardin, S. E.; Boneca, I. G.; Viala, J.; Chamaillard, M.;
Labigne, A.; Thomas, G.; Philpott, D. J.; Sansonetti, P. J. Nod2 is a
general sensor of peptidoglycan through muramyl dipeptide (MDP)
detection. J. Biol. Chem. 2003, 278, 8869–8872.
(29) Ulevitch, R. J. Therapeutics targeting the innate immune
system. Nat Rev. Immunol. 2004, 4, 512–520.
(30) Pfeifer, A.; Verma, I. M. Gene therapy: promises and problems.
Annu. Rev. Genomics Hum. Genet. 2001, 2, 177–211.
(32) For assay details, see the Supporting Information and Pub-
Chem link to AIDs.
(33) Correa, R. G.; Khan, P. M.; Askari, N.; Zhai, D.; Gerlic, M.;
Brown, B.; Magnuson, G.; Spreafico, R.; Albani, S.; Sergienko, E.; Diaz,
P. W.; Roth, G. P.; Reed, J. C. Discovery and characterization of
2-aminobenzimidazole derivatives as selective NOD1 inhibitors. Chem.
Biol. 2011, 18, 825–832.
(17) Chamaillard, M.; Hashimoto, M.; Horie, Y.; Masumoto, J.; Qiu,
S.; Saab, L.; Ogura, Y.; Kawasaki, A.; Fukase, K.; Kusumoto, S.; Valvano,
(34) Shalygina, E. E.; Kobylinskii, D. V.; Ivanovskii, S. A.; Balakin,
K. V.; Dorogov, M. V.; Toporova, T. A. Synthesis and properties of
784
dx.doi.org/10.1021/ml200158b |ACS Med. Chem. Lett. 2011, 2, 780–785